<strong>Hodgkin</strong>-<strong>Lymphom</strong> (<strong>Morbus</strong> <strong>Hodgkin</strong>) Seite 60 recurrent <strong>Hodgkin</strong>'s disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group., Journal of clinical oncology 2005 ;23(25):6181-9, 16135485 pubmed
<strong>Hodgkin</strong>-<strong>Lymphom</strong> (<strong>Morbus</strong> <strong>Hodgkin</strong>) Seite 61 Literaturverzeichnis [1] Dörffel W, Lüders H, Rühl U, Albrecht M, Marciniak H, Parwaresch R, Pötter R, Schellong G, Schwarze E, Wickmann L „Preliminary results of the multicenter trial GPOH- HD 95 for the treatment of <strong>Hodgkin</strong>'s disease in children and adolescents“, Klin Pädiatr 2003,215:139-145, 12838937 pubmed [2] Kaatsch P, Spix C. „Registry - Annual Report 2008 (Jahresbericht 2008 des Deutschen Kinderkrebsregisters)“, Technischer Bericht, Universität Mainz 2008, http:// www.kinderkrebsregister.de uri [3] Kuppers R, Klein U, Hansmann ML, Rajewsky K „Cellular origin of human B-cell lymphomas“, N Engl J Med 1999,341:1520, 10559454 pubmed [4] Flower KB, Hoppin JA, Lynch CF, Blair A, Knott C, Shore DL, Sandler DP „Cancer risk and parental pesticide application in children of Agricultural Health Study participants“, Environ Health Perspect 2004,112:631-5, 15064173 pubmed [5] Chang ET, Smedby KE, Hjalgrim H, Porwit-MacDonald A, Roos G, Glimelius B, Adami HO „Family history of hematopoietic malignancy and risk of lymphoma“, J Natl Cancer Inst 2005,97:1466, 16204696 pubmed [6] Filipovich AH, Mathur A, Kamat D, Shapiro RS „Primary inmunodeficiencies: genetic risk factors for lymphoma“, Cancer Res 1992,52:5465-5467, 1327508 pubmed [7] Knowles DM „Inmunodeficiency-associated lymphoproliferative disorders“, Mod Pathol 1999,12:200-217, 10071343 pubmed [8] Morrell D, Cromartie E, Swift M „Mortality and cancer incidence in 263 patients with ataxiatelangiectasia“, J Natl Cancer Inst 1986;77:89-92, 3459930 pubmed [9] Biggar RJ, Frisch M, Goedert JJ „Risk of cancer in children with AIDS. AIDS-Cancer Match Registry Study Group.“, JAMA 2000;284:205-9, 10889594 pubmed [10] Glaser SL, Lin RJ, Stewart SL, Ambinder RF, Jarrett RF, Brousset P, Pallesen G, Gulley ML, Khan G, O'Grady J, Hummel M, Preciado MV, Knecht H, Chan JK, Claviez A „Epstein-Barr virus-associated <strong>Hodgkin</strong>'s disease: epidemiologic characteristics in international data“, Int J Cancer 1997,70:375, 9033642 pubmed [11] Hsu JL, Glaser SL „Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications“, Crit Rev Oncol Hematol 2000,34:27-53, 10781747 pubmed [12] Wagner HJ, Schlager F, Claviez A, Bucsky P „Detection of Epstein-Barr virus DNA in peripheral blood of paediatric patients with <strong>Hodgkin</strong>'s disease by real-time polymerase chain reaction“, Eur J Cancer 2001,37:1853, 11576839 pubmed [13] Körholz D, Kluge R, Wickmann L, Hirsch W, Lüders H, Lotz I, Dannenberg C, Hasenclever D, Dörffel W, Sabri O „Importance of F18-fluorodeoxy-D-2-glucose positron emissi-